- Home
- AMGN
AMGN
Amgen Inc.
as 02-21-2025 4:00pm EST
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
| Founded: | 1980 | Country: | United States |
| Employees: | N/A | City: | THOUSAND OAKS |
| Market Cap: | 156.2B | IPO Year: | N/A |
| Target Price: | $322.26 | AVG Volume (30 days): | 3.0M |
| Analyst Decision: | Buy | Number of Analysts: | 21 |
| Dividend Yield: | Dividend Payout Frequency: | Quarterly | |
| EPS: | 7.56 | EPS Growth: | -39.47 |
| 52 Week Low/High: | $253.30 - $346.85 | Next Earning Date: | 02-04-2025 |
| Revenue: | $33,424,000,000 | Revenue Growth: | 18.57% |
| Revenue Growth (this year): | 5.39% | Revenue Growth (next year): | 1.55% |
Stock Insider Trading Activity of Amgen Inc. (AMGN)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Gordon Murdo | AMGN | EVP, Global Commercial Ops | Feb 11 '25 | Sell | $294.79 | 8,771 | $2,585,644.31 | 44,186 | |
| Graham Jonathan P | AMGN | EVP & Gen. Counsel & Secy. | Feb 7 '25 | Sell | $293.12 | 25,045 | $7,341,122.78 | 28,987 | |
| Grygiel Nancy A. | AMGN | SVP & CCO | Feb 5 '25 | Sell | $304.47 | 1,589 | $483,807.76 | 7,210 |
Latest Amgen Inc. News
AMGN Breaking Stock News: Dive into AMGN Ticker-Specific Updates for Smart Investing
Zacks
a day ago
4 Seniors & Aging Demographics Stocks to Watch Right Now
Zacks
a day ago
Here is What to Know Beyond Why Amgen Inc. (AMGN) is a Trending Stock
Simply Wall St.
a day ago
There May Be Some Bright Spots In Amgen's (NASDAQ:AMGN) Earnings
Zacks
2 days ago
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
MT Newswires
2 days ago
Bernstein Adjusts Amgen Price Target to $350 From $380, Maintains Outperform Rating
MT Newswires
3 days ago
Argus Cuts Price Target on Amgen to $330 From $360, Maintains Buy Rating
Argus Research
3 days ago
Analyst Report: AMGEN Inc.
Argus Research
3 days ago
Market Update: AMGN, KO, KR, KSS, ANET
Compare AMGN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "AMGN Amgen Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.